NIH funding profile · Philadelphia, PA · Research institute
Fox Chase Cancer Center NIH Funding
NIH RePORTER recipient name: Research Inst of Fox Chase Can Ctr
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
Fox Chase Cancer Center received $28.6M in NIH award funding in fiscal year 2026 across 43 award records and 44 principal investigators. That ranks #198 of 2,407 NIH-funded institutions and #12 in Pennsylvania, down 5.4% from FY2025.
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
FY2026 NIH funding
$28.6M
−5.4% vs FY2025
National rank
#198
Down 5 places from #193 vs FY2025
Rank in Pennsylvania
#12
1.3% of Pennsylvania NIH funding · up 1 place from #13
Awards · PIs
43
44 investigators · 3 new projects
NIH funding trend, FY2022–FY2026
Fox Chase Cancer Center received $130.2M in NIH awards over these five fiscal years. Annual funding moved +31.3% from FY2022 to FY2026. Its best national rank in the period was #193 (FY2025).
NIH institutes funding Fox Chase Cancer Center, FY2026
6 NIH institutes and centers administered awards here in FY2026. The largest, the National Cancer Institute (NCI), accounted for 63.9% of the institution's NIH funding across 28 awards.
- NCI · National Cancer Institute$18.2M · 63.9%
28 awards · vs FY2025: −0.2%
- NIAID · National Institute of Allergy and Infectious Diseases$3.9M · 13.6%
3 awards · vs FY2025: −28.8%
- NIGMS · National Institute of General Medical Sciences$3.1M · 10.9%
6 awards · vs FY2025: −15.0%
- NIMHD · National Institute on Minority Health and Health Disparities$2.4M · 8.4%
3 awards · vs FY2025: +26.6%
- NHLBI · National Heart, Lung, and Blood Institute$699K · 2.4%
2 awards · vs FY2025: +4.9%
- NIDDK · National Institute of Diabetes and Digestive and Kidney Diseases$249K · 0.9%
1 award · vs FY2025: 0.0%
Award mechanism mix
Share of NIH award dollars by activity-code family in FY2026, with the FY2022 share for comparison. R01-equivalent research grants were 55.0% of funding.
- R01-equivalent55.0% · FY22 52.8%
- Centers & program projects (P)18.0% · FY22 12.0%
- Other research (R)16.0% · FY22 14.7%
- Cooperative agreements (U)10.3% · FY22 8.8%
- Institutional training (T)0.6% · FY22 0.0%
- Career development (K)0.0% · FY22 0.0%
- Contracts (N)0.0% · FY22 11.7%
Top activity codes, FY2026
| Code | Awards | Funding | Share | Average award |
|---|---|---|---|---|
| R01 | 21 | $14.4M | 50.4% | $685K |
| R35 | 6 | $3.1M | 10.9% | $517K |
| P30 | 1 | $2.8M | 9.8% | $2.8M |
| P01 | 1 | $2.4M | 8.2% | $2.4M |
| U54 | 1 | $1.5M | 5.3% | $1.5M |
| R37 | 2 | $1.3M | 4.7% | $667K |
| UH3 | 3 | $1.2M | 4.1% | $390K |
| R00 | 3 | $747K | 2.6% | $249K |
| R34 | 1 | $314K | 1.1% | $314K |
| R21 | 1 | $264K | 0.9% | $264K |
| UH2 | 1 | $264K | 0.9% | $264K |
| T32 | 1 | $175K | 0.6% | $175K |
Largest FY2026 awards
The biggest single award records by FY2026 dollars. Each links to its NIH RePORTER project page.
- Comprehensive Cancer Center Program at Fox Chase (opens NIH RePORTER)
5P30CA006927-57 · NCI
$2.8MP30
- Molecular Basis for γδ T Lineage Specification (opens NIH RePORTER)
5P01AI102853-12 · NIAID
$2.4MP01
- Promoting Effective Clinical Communication about Sexual Health after Gynecologic Cancer: A Randomized Controlled Trial of a Patient-Focused Intervention (opens NIH RePORTER)
4R01CA285674-03 · NCI
$1.6MR01
- Cancer Prevention-Interception Targeted Agent Discovery Program at Fox Chase Cancer Center (opens NIH RePORTER)
5U54CA272686-05 · NCI
$1.5MU54
- Compensatory Mechanisms that Promote Homologous Recombination in BRCA1 Mutant Cancers (opens NIH RePORTER)
4R01CA214799-08 · NCI
$1.2MR01
- Examining the Relationship between Residential History at Midlife and Prostate Cancer Outcomes (opens NIH RePORTER)
4R01MD018146-04 · NIMHD
$1.0MR01
Recently started projects
The latest new (Type 1) FY2026 awards by notice date, out of 3 new projects NIH funded here this year.
- Reinforcing the Cancer Prevention Potential of Aspirin in Lynch Syndrome (ReCAPP-LS): Development and Piloting of an Electronic Decision Support Tool (opens NIH RePORTER)
1R34CA317545-01 · NCI · Notice Sep 17, 2026
$314KR34
- Clinical Translation of a Urine-Based Biomarker for the Detection of Residual Disease in Radical Cystectomy Candidates (opens NIH RePORTER)
1UH2CA299386-01A1 · NCI · Notice May 14, 2026
$264KUH2
- Intratumor Heterogeneity as a Correlate of Clinical Outcome in Patients Avoiding Radical Cystectomy (opens NIH RePORTER)
1R01CA307511-01 · NCI · Notice Apr 3, 2026
$766KR01
Other NIH-funded institutions in Pennsylvania
| # | Institution | Funding |
|---|---|---|
| 7 | Temple UniversityPhiladelphia, PA | $61.5M |
| 8 | Drexel UniversityPhiladelphia, PA | $54.5M |
| 9 | Wistar InstitutePhiladelphia, PA | $48.9M |
| 10 | NRG Oncology Foundation, Inc.Philadelphia, PA | $32.4M |
| 11 | ECOG-ACRIN Medical Research FoundationPhiladelphia, PA | $30.3M |
| 12 | Fox Chase Cancer CenterPhiladelphia, PA | $28.6M |
| 13 | Carnegie Mellon UniversityPittsburgh, PA | $28.2M |
| 14 | Cognition Therapeutics, Inc.Pittsburgh, PA | $16.5M |
| 15 | Geisinger ClinicDanville, PA | $11.8M |
Nearby in the national ranking
| # | Institution | Funding |
|---|---|---|
| 195 | Fisher Bioservices, Inc.Rockville, MD | $29.2M |
| 196 | Texas Biomedical Research InstituteSan Antonio, TX | $28.8M |
| 197 | Tufts Medical CenterBoston, MA | $28.8M |
| 198 | Fox Chase Cancer CenterPhiladelphia, PA | $28.6M |
| 199 | Mayo Clinic ArizonaScottsdale, AZ | $28.5M |
| 200 | Georgia State UniversityAtlanta, GA | $28.3M |
| 201 | Carahsoft Technology CorporationReston, VA | $28.2M |
Similar research institutes and nonprofits
| # | Institution | Funding |
|---|---|---|
| 189 | ECOG-ACRIN Medical Research FoundationPhiladelphia, PA | $30.3M |
| 192 | RAND CorporationSanta Monica, CA | $29.3M |
| 193 | Children's Research InstituteWashington, DC | $29.3M |
| 196 | Texas Biomedical Research InstituteSan Antonio, TX | $28.8M |
| 198 | Fox Chase Cancer CenterPhiladelphia, PA | $28.6M |
| 199 | Mayo Clinic ArizonaScottsdale, AZ | $28.5M |
| 205 | Banner HealthPhoenix, AZ | $26.6M |
About these numbers
Source: the public NIH RePORTER API, refreshed October 16, 2026. See our data methodology and the guide to reading NIH funding rankings by university.
- Who is countedAwards made to NIH recipient organization code 1190002 (Research Inst of Fox Chase Can Ctr). A university's medical school, affiliated hospital, or other campuses can be separate NIH recipients with their own totals.
- What is countedTotal award amount (direct plus indirect) obligated in each fiscal year for grants, cooperative agreements, training awards, SBIR/STTR, and R&D contracts. Subprojects, intramural research, and interagency agreements are excluded.
- InstitutesEach award is credited in full to its administering institute, even when other institutes co-fund it.
- SubawardsNIH reports the prime recipient only, so research this institution performs under another organization's grant is not included here.